Mostrar el registro sencillo del ítem
Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions
dc.contributor.author | Gago Dominguez, Manuela | |
dc.contributor.author | Matabuena M | |
dc.contributor.author | Redondo CM | |
dc.contributor.author | Patel SP | |
dc.contributor.author | Carracedo Álvarez, Ángel | |
dc.contributor.author | Ponte SM | |
dc.contributor.author | Martinez ME | |
dc.contributor.author | Castelao JE | |
dc.date.accessioned | 2022-05-24T12:15:05Z | |
dc.date.available | 2022-05-24T12:15:05Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32764699 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16836 | |
dc.description.abstract | Multiple studies have found the neutrophil to lymphocyte ratio (NLR) to be associated with adverse breast cancer (BC) prognosis and survival. Very limited data exist on the role of NLR and risk of BC. The BREOGAN study is a population-based case-control study conducted in Galicia, Spain. We examined the WBC- and NLR-BC relationships. The risk of BC increased with increasing levels of neutrophils percentage (NE%) (multivariable OR for the highest category (95% CI) = 2.14 (1.39-3.32), P-trend < 0.001) and of the NLR (multivariable OR for the highest category (95% CI) = 1.93 (1.26-2.97), P-trend < 0.001). Lymphocytes absolute (L#) and percentage (L%) were associated with a decreased risk of BC (multivariable OR for the highest category (95% CI) = 0.54 (0.35-0.83), and 0.51 (0.33-0.79), P-trend = 0.001 and < 0.001, respectively). The NLR-BC association was more pronounced among Luminal A BC (multivariable OR for the highest category (95% CI) = 2.00 (1.17-3.45), P-trend < 0.001), HER2-negative BC (multivariable OR for the highest category (95% CI) = 1.87 (1.16-3.02), P-trend < 0.001), and those with high total cholesterol and low H2O2 levels. | en |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject.mesh | Risk | * |
dc.subject.mesh | Menopause | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Breast Neoplasms | * |
dc.subject.mesh | Neoplasm Staging | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Lymphocytes | * |
dc.subject.mesh | Adolescent | * |
dc.subject.mesh | Lymphocyte Count | * |
dc.subject.mesh | Neoplasm Grading | * |
dc.subject.mesh | Neutrophils | * |
dc.subject.mesh | Pregnancy | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Case-Control Studies | * |
dc.title | Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions | en |
dc.type | Journal Article | es |
dc.authorsophos | Gago-Dominguez, M Matabuena, M Redondo, CM Patel, SP Carracedo, A Ponte, SM Martinez, ME Castelao, JE | |
dc.identifier.doi | 10.1038/s41598-020-70077-z | |
dc.identifier.pmid | 32764699 | |
dc.identifier.sophos | 41952 | |
dc.issue.number | 1 | es |
dc.journal.title | Scientific Reports | es |
dc.organization | Servizo Galego de Saúde::Dirección Xeral de Asistencia Sanitaria::Fundación Pública Galega de Medicina Xenómica | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | es |
dc.rights.accessRights | openAccess | |
dc.subject.decs | estudios de casos y controles | * |
dc.subject.decs | menopausia | * |
dc.subject.decs | estadificación de neoplasias | * |
dc.subject.decs | neoplasias de la mama | * |
dc.subject.decs | recuento de linfocitos | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | embarazo | * |
dc.subject.decs | adulto | * |
dc.subject.decs | humanos | * |
dc.subject.decs | riesgo | * |
dc.subject.decs | gradación neoplásica | * |
dc.subject.decs | adolescente | * |
dc.subject.decs | linfocitos | * |
dc.subject.decs | neutrófilos | * |
dc.subject.keyword | FPGMX | es |
dc.subject.keyword | IDIS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 10 | es |